| pubmed-article:20716876 | pubmed:abstractText | Bone metastasis is a frequent complication of malignant cancer. Previous clinical trials of bone metastasis have largely focused on skeletal related events (SREs) as objective end-points. However, a subjective health-related outcome such as quality of life (QOL) is also a first-priority principle for all patients with malignant cancer. In response to the need for a comprehensive module to evaluate bone metastasis-specific QOL, the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group has developed a Quality of Life Questionnaire for patients with Bone Metastases (EORTC QLQ-BM22). In this study, we introduce the official Japanese version of the EORTC QLQ-BM22 as a module to evaluate QOL in patients with bone metastasis. This module has been developed to be used together with the EORTC QLQ-C30, a QOL scale for patients with cancer, or with its shortened version, EORTC QLQ-C-15-PAL. | lld:pubmed |
